MITF and melanoma: Moreover, our study indicates that (1) AXL is not an unambiguous marker of resistance to targeted therapeutics; (2) the development of resistance is accompanied by increased percentages of NGFR-positive cells and reduced percentages of MITF-positive cells in the majority but not all melanoma cell populations.